AC
PSTX

Aaron Cowen’s Poseida Therapeutics, Inc. Common Stock PSTX Stock Holding History

Aaron Cowen’s Portfolio PSTX Stock Details PSTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-80,000
Closed -$710K – 128
2020
Q3 		$710K Buy
+80,000
New +$910K 0.01% 89

Other funds holding PSTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $143M AUM 102.52% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Aaron Cowen's PSTX Position: Q4 2020 in Review

Aaron Cowen sold out of Poseida Therapeutics, Inc. Common Stock (PSTX) in Q4 2020, closing a stake of 80,000 shares — an estimated $710K sold.

Aaron Cowen first reported a position in PSTX in Q3 2020 and held it in 1 quarter. The position peaked at $710K in Q3 2020. 56 funds tracked by Wall St. Rank hold PSTX as of Q4 2020.

  • Aaron Cowen reported no remaining Poseida Therapeutics, Inc. Common Stock position as of Q4 2020 after selling out during the quarter.
  • Aaron Cowen sold 80,000 Poseida Therapeutics, Inc. Common Stock shares in Q4 2020, an estimated $710K.
  • Aaron Cowen first reported a position in Poseida Therapeutics, Inc. Common Stock in Q3 2020 and held it in 1 quarter.
  • Aaron Cowen's Poseida Therapeutics, Inc. Common Stock position peaked at $710K in Q3 2020.
  • 56 funds tracked by Wall St. Rank held Poseida Therapeutics, Inc. Common Stock as of Q4 2020.

Based on Suvretta Capital Management's 13F filing for Q4 2020, filed 16 Feb 2021.